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Reduced expression of Paternally 
Expressed Gene-3 enhances 
somatic cell reprogramming 
through mitochondrial activity 
perturbation
Ilda Theka1,2, Francesco Sottile1,2, Francesco Aulicino1,2, Alvaro Castells Garcia1,2 &  
Maria Pia Cosma1,2,3
Imprinted genes control several cellular and metabolic processes in embryonic and adult tissues. 
In particular, paternally expressed gene-3 (Peg3) is active in the adult stem cell population and 
during muscle and neuronal lineage development. Here we have investigated the role of Peg3 in 
mouse embryonic stem cells (ESCs) and during the process of somatic cell reprogramming towards 
pluripotency. Our data show that Peg3 knockdown increases expression of pluripotency genes in 
ESCs and enhances reprogramming efficiency of both mouse embryonic fibroblasts and neural stem 
cells. Interestingly, we observed that altered activity of Peg3 correlates with major perturbations of 
mitochondrial gene expression and mitochondrial function, which drive metabolic changes during 
somatic cell reprogramming. Overall, our study shows that Peg3 is a regulator of pluripotent stem cells 
and somatic cell reprogramming.
Paternally expressed gene-3 (Peg3, also known as Pw1) is an imprinted gene that encodes a Krüppel-type (C2H2) 
zinc finger protein1. During embryo development, Peg3 expression is detected upon gastrulation, where it 
plays a major role in muscle and neuronal lineage development1, 2. In adult tissues, Peg3 is expressed in several 
stem cell compartments, thus it has been considered a marker for competent self-renewing adult stem cells3. 
Moreover defects in PEG3 expression have been identified in human gynecologic cancer4, 5 and glioma cell lines6. 
Accordingly, PEG3 plays a tumor suppressor role in many types of cancers and exogenous PEG3 overexpression 
in glioma cell lines resulted in loss of tumorigenicity7. Furthermore, Peg3 is involved in apoptosis induction, 
more specifically it can contribute to p53 activation and Bax translocation8, 9. Nevertheless, the mechanisms 
behind Peg3 action in different cellular contexts (both in embryonic and adult tissues) still remain obscure. Peg3 
could possibly control cell proliferation10 and cellular metabolism by directly regulating mitochondrial gene 
expression11. Indeed, Peg3 can bind and control the expression of mitochondrial related genes, including Tufm, 
Slc25a29, Mrpl45, among others12. Mitochondria not only provide energy to the cells but also control several 
molecular processes, such as cell growth, cell cycle, and cell death13. Moreover mitochondrial activity determines 
and regulates metabolic states that are important for the maintenance of cell homeostasis and for driving cell fate 
transition14.
Here we investigated the role of Peg3 in pluripotent mouse embryonic stem cells (ESCs), which are highly pro-
liferative and characterized by a glycolytic metabolism. During ESC differentiation a transition towards oxidative 
phosphorylation (OXPHOS) occurs and thus correlates with high mitochondria activity15–19. In contrast, the met-
abolic switch from OXPHOS towards glycolysis has been shown to occur during somatic cell reprogramming18–20. 
We show that low levels of Peg3 are associated with pluripotency and enhance somatic cell reprogramming effi-
ciency by modulating mitochondrial activity.
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Results
Peg3/Pw1 endogenous expression levels anti-correlate with pluripotency state. Peg3/Pw1 is 
expressed in several adult tissues and in particular in adult stem cells3. However, its involvement in the regula-
tion of molecular processes controlling pluripotency has not been described. To investigate this possibility, we 
first analyzed its endogenous expression levels in E14 mouse embryonic stem cells (ESCs). Peg3 was expressed 
at very low levels in ESCs when compared to both mouse embryonic fibroblasts (MEFs) and neural stem cells 
(NSCs), both at mRNA and protein level (Fig. 1A–D). In addition, both Peg3 transcript and protein levels strongly 
increased during embryoid bodie (EB) formation (Supplementary Figure 1A and B) and in E14 ESCs differenti-
ated toward NSCs21, 22 (Supplementary Figure 1C and D).
Interestingly, even though Peg3 was expressed at very low levels in ESCs, we observed a further transcrip-
tional downregulation when ESCs were grown in 2i-Lif medium (2i-Lif) for 4 days as compared to the serum-Lif 
medium (Serum) (Fig. 1E). ESCs grown in 2i-Lif medium (a defined serum free ESC medium containing the 
GSK3β and MEK inhibitors)23, can reach the ground state of pluripotency, which resembles the inner cell mass 
(ICM)24, as confirmed by the increased expression of pluripotency genes such as Nanog and Rex1 (Fig. 1E). 
Moreover, Peg3 transcriptional levels decreased in induced pluripotent stem cell (iPSCs) when compared to MEFs 
(Fig. 1F). These observations indicate that Peg3 levels anti-correlate with pluripotency state and are higher in 
differentiated cells.
Peg3 silencing positively regulates pluripotency and self-renewal of mouse ESCs. Given that 
Peg3 increased at the onset of differentiation and it was downregulated in ESCs cultured in 2i-Lif medium, we 
asked whether Peg3 knockdown (KD) could affect self-renewal and pluripotency. To address this hypothesis we 
silenced Peg3 (shPeg3) in ESCs, both stably and transiently, by using either pLKO-shCtrl (a vector carrying a 
control short hairpin with no predicted targets in the mouse transcriptome) or pLKO-shPeg3 construct, which 
carries a short hairpin targeting Peg3. Both shCtrl and shPeg3 contructs contain a hygromycin resistance cassette, 
which allow us to select the infected cells25. The pluripotency markers Nanog, Sox2, Oct4 and Rex1 increased after 
Peg3 downregulation (Fig. 1G and Supplementary Figure 1E). In addition, to analyze the effect of Peg3 KD on 
ESC self-renewal, we performed alkaline phosphatase colony-forming cell (AP-CFC) assay. The alkaline phos-
phatase membrane-bound enzyme is one of the key markers to identify pluripotent stem cells, such as ESCs26. 
Interestingly Peg3 transient inhibition resulted in higher number of alkaline phosphatase positive (AP+) ESC col-
onies when compared to the control (shCtrl). On the contrary, the number of AP+ colonies decreased after Oct4 
transient silencing, which we used as negative control (Fig. 1H and I). Oct4 has been described to impair ESC 
self-renewal capability27, which is consistent with our data. Moreover, Peg3 transient KD induced the expression 
of the pluripotency markers, such as Nanog and Oct4, which, on the contrary, were downregulated after Oct4 
depletion (Supplementary Figure 1E).
To further confirm its effect on pluripotency, we stably silenced Peg3 in another ESC line (REX1-dGFP ESCs), 
which carried a destabilized GFP (dGFP) under the control of the endogenous Rex1 promoter23. REX1-dGFP 
ESCs carrying Peg3 KD displayed significant increase in the percentage of GFP positive (GFP+) cells when 
compared to control (shCtrl), accordingly the number of GFP negative (GFP−) cells decreased (Supplementary 
Figure 1F). However, even though, Peg3 KD resulted in higher percentage of GFP+ cells, its depletion alone was 
not sufficient to induce the ground pluripotency state in ESCs. Indeed, the GFP+ cells in 2i-Lif medium were 
around 95 percent, as previously reported23, in both shCtrl and shPeg3 infected ESCs (Supplementary Figure 1F). 
Moreover, when we induced ESC differentiation in NSCs the difference in the GFP+/GFP− ratio between shCtrl 
and shPeg3 conditions was maintained over time, suggesting a delay in the differentiation potential of the Peg3 
depleted ESCs (Supplementary Figure 1G). Of note, as in the case of E14 (Fig. 1G), Peg3 KD was efficient in 
REX1-dGFP ESCs and it was maintained silenced during differentiation (Supplementary Figure 1H and I).
Peg3 silencing enhances somatic cell reprogramming of MEFs and NSCs. Based on the observa-
tions made in ESCs, we asked whether Peg3 could control the reversion of differentiated cells back to the pluripo-
tent state. To address this hypothesis we decided to investigate the effect of Peg3 KD during induced pluripotent 
stem cell (iPSC) generation starting both from MEFs and NSCs (Fig. 2A). First, we infected transgenic 4F-MEFs, 
obtained from the “reprogrammable” mice carrying the Oct4, Sox2, Klf4, c-Myc (OKSM) doxycycline (DOX) 
inducible cassette28 with either pLKO-shCtrl or pLKO-shPeg3 vectors, as previously described25. Subsequently we 
induced OKSM expression and we evaluated reprogramming efficiency by counting the number of NANOG pos-
itive (NANOG+) iPSC clones at day 16 (Fig. 2A). Interestingly Peg3 KD enhanced MEF reprogramming process 
resulting in a higher number of generated NANOG+ clones when compared to the control (Fig. 2B). Importantly, 
by analyzing Peg3 expression levels at day 5 of reprogramming we confirmed that the silencing was efficient also 
after OKSM induction (Fig. 2C). The generated iPSC clones obtained from both shCtrl and shPeg3 infected 
4F-MEFs expressed different pluripotency markers, including NANOG, OCT4, SOX2 and E-cadherin (Fig. 2D). 
To then address if Peg3 can enhance the kinetic of iPSC generation, we performed FACS analysis for E-cadherin 
expression at day 0 and 5 of reprogramming. E-cadherin is an early reprogramming marker and its expression 
is detected upon cellular aggregation and mesenchymal-to-epithelial transition (MET) that occurs at the initial 
reprogramming stages25, 29, 30. Remarkably, shPeg3 transduced 4F-MEFs expressed higher levels of E-cadherin 
already at day 0 with respect to control (shCtrl), as shown by the increase of percentage of E-cadherin+ cells 
(Fig. 2E and F). During reprogramming E-cadherin expression gradually increased in both conditions, however 
its expression was significantly higher in Peg3 depleted 4F-MEFs when compared to the control (Fig. 2E and F). 
As a consequence, Peg3 depleted 4F-MEFs aggregated faster when compared to the control, as shown in Fig. 2G. 
Interestingly, Peg3 inhibition was able to induce E-cadherin expression also in the absence of c-Myc. Indeed, OKS 
infected MEFs showed an increase in the percentage of E-cadherin+ cells at day 0 and at day 12 of reprogramming 
in the absence of Peg3 (Supplementary Figure 2A and B). In absence of c-Myc, however, the reprogramming 
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Figure 1. Peg3 expression levels anti-correlate with pluripotency state. (A,C) Quantitative real-time 
PCR analysis of endogenous Peg3 expression levels in ESCs, MEFs (A) and NSCs (C) (n = 3 independent 
experiments). (B,D) Representative western-blots (out of n = 2 independent experiments) showing endogenous 
PEG3 protein levels in ESCs versus MEFs (B) and versus NSCs (D). (E,F) Quantitative real-time PCR analysis 
showing endogenous Peg3 expression in 2i-Lif media (2i-Lif) versus serum-Lif (Serum) (n = 3 independent 
experiments) (E), and in induced pluripotent stem cell (iPSC) clones versus MEFs (n = 3 technical replicates) 
(F). (G) Quantitative real-time PCR analysis of pluripotency gene expression levels in ESCs after Peg3 stable 
silencing (n = 3 independent experiments). (H,I) Representative bright field and quantification of alkaline 
phosphatase positive (AP+) colonies represented as fold change and counted at day 7 of the AP+-CFC assay 
(n = 3 independent experiments). shOct4 silencing construct was used as a negative control. (A,C,E,G,I) Data 
are represented as fold change (2−ΔΔCt) and means of n = 3 independent experiments ± SE. Asterisks indicate 
statistical significance calculated by unpaired two-tailed t test analysis (*p < 0.05; **p < 0.01). For western-blot 
analysis β-Tubulin was used as loading control and densitometric analysis was carried out by using ImageJ 
software. The quantification reflects the relative amounts as a ratio of each protein band relative to their loading 
control.
www.nature.com/scientificreports/
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Figure 2. Peg3 silencing enhances MEF and NSC reprogramming efficiency. (A) Experimental scheme of 
MEF and NSC reprogramming infected with either shCtrl or shPeg3. MEFs and NSCs were infected with either 
shCtrl or shPeg3, hygromycin selected and re-plated in equal number before inducing reprogramming. The 
number of NANOG+ iPSC clones was counted at day 16 of reprogramming. (B) Number of NANOG+ iPSC 
clones (represented as fold change) obtained from shCtrl and shPeg3 infected 4F-MEFs (n = 3 independent 
experiments). (C) Quantitative real-time PCR analysis represented as fold change showing Peg3 silencing 
efficiency at day 5 of MEF reprogramming (n = 3 independent experiments) (D) Representative fluorescence 
microscopy images of shCtrl and shPeg3 transduced iPSC clones expressing the pluripotency markers, such 
as NANOG, OCT4, SOX2 and E-cadherin. (E,F) Representative FACS profile showing E-cadherin expression 
in shCtrl and shPeg3 infected 4F-MEFs at day 0 (upper plot) and 5 (lower plot) of reprogramming (E) and its 
quantification (F). Data are represented as means of n = 3 independent experiments ± SD. (G) Representative 
bright field images of 4F-MEFs at day 5 of reprogramming infected with either shCtrl (upper) or shPeg3 (lower). 
(H) Quantitative real-time PCR analysis represented as fold change, showing Thy1 and EpCAM expression 
(represented ad fold change) in shCtrl and shPeg3 infected 4F-MEFs at day 5 of reprogramming. (I) Number of 
NANOG+ iPSC clones (represented as fold change and n = 3 independent experiments) obtained from shCtrl 
and shPeg3 infected NSCs. (J) Quantitative real-time PCR analysis represented as fold change showing Peg3 
silencing efficiency at day 5 of NSC reprogramming. (B,C,H,I,J) Data are represented as fold change and means 
of n = 3 independent experiments ± SE. Asterisks indicate statistical significance calculated by unpaired two-
tailed t test analysis (*p < 0.05; **p < 0.01; ***p < 0.001). Nuclei were stained with DAPI. Scale bar is 20 μm 
(D), 200 μm (G).
www.nature.com/scientificreports/
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process was delayed and was less efficient, when compared to the OKSM induction, as indicated by the lower 
number of E-cadherin+ cells during reprograming (Fig. 2F and Supplementary Figure 2B), consistent with previ-
ously reported data31. These results suggest that Peg3 KD has a positive effect on reprogramming and enhances its 
efficiency both in the presence and absence of c-Myc. However, we also observed that Peg3 silencing alone is not 
sufficient to replace the effect of c-Myc.
To further strengthen our data, we also analyzed the expression levels of Thy1 and EpCAM, mesenchymal 
and epithelial marker, respectively25, 30, again at day 5 of reprogramming. As expected, Peg3 inhibition resulted in 
lower levels of Thy1 and higher expression of EpCAM, suggesting that Peg3 could act already at the reprogram-
ming onset (Fig. 2H).
Moreover, to investigate whether the effect of Peg3 KD on reprogramming could be extended to other cell 
types, we also infected NSCs with either pLKO-shCtrl or pLKO-shPeg3 constructs and we induced reprogram-
ming by overexpressing 3 factors, OCT4, KLF4, c-MYC (OKM), since NSCs already express high level of endog-
enous SOX232 (Fig. 2A). As in the case of the MEFs, we observed more than two fold increase in the number of 
generated NANOG+ positive clones (Fig. 2I and Supplementary Figure 2C) upon Peg3 silencing (Fig. 2J).
The effect of Peg3 KD was also tested by using the lentiviral-based miR30 inducible silencing system (pIN-
DUCER10, miR-RUP) harboring a different Peg3 shRNA activated upon DOX addition. This construct also con-
tained a constitutive puromycin resistance cassette and an RFP coding sequence, expressed along with the shRNA 
upon DOX treatment33 (Supplementary Figure 2D). Thus, we transduced E14 ESCs with the inducible Peg3 KD 
lentiviral construct (pIND-shPeg3), selected the cells with puromycin and analyzed the RFP expression both 
before and after DOX addition. Almost 90% of the infected cells were RFP positive (RFP+) already at 48 hours 
after DOX addition (Supplementary Figure 2E and F) and they showed an increase in pluripotency gene expres-
sion upon Peg3 silencing (Supplementary Figure 2G). Moreover, the pIND-shPeg3 DOX-dependent silencing 
along with either OKSM or OKM expression (Supplementary Figure 2H) increased the number of NANOG+ 
iPSC clones (Supplementary Figure 2I and J), (around 5 folds) starting from both wild type (WT) MEFs and 
NSCs (Supplementary Figure 2K and L). Peg3 silencing efficiency during reprogramming was around 50% at day 
5 (Supplementary Figure 2M and N).
In conclusion, these data show that inhibition of Peg3 induces upregulation of pluripotency genes in ESCs and 
it enhances the efficiency of the reprogramming process starting from both MEFs and NSCs.
PEG3 overexpression impairs somatic cell reprogramming. We asked whether Peg3 overexpression 
in ESCs and during iPSC generation process could perturb pluripotency and somatic cell reprogramming effi-
ciency, respectively. To this aim, Peg3 coding sequence was cloned under the constitutive EF1α promoter in 
a lentiviral vector carrying either a mCherry (EF1α-Peg3-SV40-mCherry) or a puromycin resistance cassette 
(EF1α-Peg3-SV40-PURO) driven by the constitutive SV40 promoter that allowed us to detect or select infected 
cells. In parallel, we also used an empty lentiviral vector (EV) as a control (Fig. 3A). After stable expression of 
either EF1α-Peg3-SV40-mCherry or EF1α-Peg3-SV40-PURO in ESCs we did not detect a strong upregulation 
of Peg3, which increased around 2-3 fold with respect to the control (EV) (Fig. 3B and C). Nevertheless, when 
we FACS-sorted the mCHERRY positive (mCHERRY+) ESCs and re-plated them in equal number to perform 
AP+-CFC assay we observed a reduction in the AP signal intensity and in the number of AP+ colonies after Peg3 
overexpression when compared to the control (EV) (Fig. 3D and E). In addition, we performed transient Peg3 
overexpression to further investigate its effect. In this case we used the EF1α-Peg3-SV40-mCherry construct 
in parallel with the EF1α-EV-SV40-mCherry vector (Supplementary Figure 3A), which allowed us to evaluate 
the efficiency of transfection by analyzing the FACS profile of the mCHERRY+ population. The transfection 
efficiency was comparable between EV and PEG3 overexpressing ESCs (Supplementary Figure 3B) and we fur-
ther confirmed the PEG3 upregulation by analyzing the protein levels (Supplementary Figure 3C). Interestingly, 
by performing AP+-CFC assay we observed a decrease in the number of AP+ colonies along with high PEG3 
levels (Supplementary Figure 3D and E), consistent with the phenotype observed in the stable Peg3 expression 
experiments.
Peg3 has been shown to be involved in cell apoptosis, acting together with p538, 34. However, here, we excluded 
this possibility by performing AnnexinV (AnxV) staining and flow cytometry analysis (Supplementary Figure 3F 
and G). Indeed, within the mCHERRY+ population the number of AnxV positive cells remained very low in both 
EV and PEG3 overexpressing cells (around 1–2%).
Next, to investigate whether Peg3 overexpression could affect differentiation, we induced EB formation from 
ESCs overexpressing either EF1α-Peg3-SV40-mCherry (Fig. 3F) or EF1α-Peg3-SV40-PURO (Fig. 3G). In both 
cases we observed normal EB morphology. Nevertheless, the differentiation markers (Gata6, Fgf5, Gata4) corre-
sponding to the three germ layers were higher in the EBs derived from EF1α-Peg3-SV40-mCherry overexpress-
ing ESCs, when compared to the control (EV) (Fig. 3H). These data suggest that Peg3 overexpression confers 
ESCs a higher propensity to differentiate.
We, then, investigated if Peg3 overexpression could impair reprogramming. To this aim, we infected 4F-MEFs 
with the EF1α-Peg3-SV40-mCherry lentiviral construct and induced OKSM expression through DOX addition. 
At day 5 of reprogramming we FACS-sorted either mCHERRY+ or mCHERRY− cells to enrich for both popu-
lations (with or without PEG3 overexpression) (Fig. 3I) and re-plated them in equal number on mitomycin C 
inactivated MEFs. Interestingly, after 8 days of DOX treatment since FACS-sorting, some iPSC clones started to 
appear only in the mCHERRY− cell population. On the contrary the mCHERRY+ cells needed additional days to 
be reprogrammed, and iPSC colonies were detected only after 5 extra days of DOX treatment (Fig. 3J). Therefore, 
at day 18 the total number of NANOG+ clones derived from the mCHERRY+ population was much lower if com-
pared to the mCHERRY− derived cells (Fig. 3K). As expected the mCHERRY+ cells showed higher level of Peg3 
(around 3-fold) when compared to the mCHERRY− cells (Fig. 3L). These data suggest that high levels of Peg3 are 
detrimental for the reprogramming process.
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Figure 3. Peg3 overexpression impairs somatic cell reprogramming. (A) Representative scheme of EF1α-Peg3-
SV40-mCherry and EF1α-Peg3-SV40-Puro lentiviral vectors. (B,C) Quantitative real-time PCR analysis of 
Peg3 expression level after either EV or PEG3 transduction by using either EF1α-EV/Peg3-SV40-mCHERRY 
(B) (n = 3 independent experiments) or -PURO (C) (n = 3 technical replicates) (D) Representative AP+-CFC 
assay of ESCs transduced either with EF1α-EV-SV40-mCherry or EF1α-Peg3-SV40-mCherry, plated in 
equal number (102 cells/cm2 for each condition) and cultured for additional 7 days. (E) Quantification of AP+ 
colonies at day 7 of AP+-CFC assay. Data are represented as means of n = 3 independent experiments ± SE. 
(F,G) Representative bright field images of EV and PEG3 infected EBs at day 5 of the differentiation protocol 
transduced with either EF1α-EV/Peg3-SV40-mCherry (F) or EF1α-EV/Peg3-SV40-Puro construct (G). (H) 
Quantitative real-time PCR showing differentiation markers expression levels (n = 3 technical replicates). Data 
are represented as fold change (2−ΔΔCt) and means ± SD. (I) Experimental scheme and plots showing FACS-
sorting strategy of mCHERRY+ and mCHERRY− MEFs at day 5 of reprogramming. The non infected (NI) 
MEFs were used as a control. At day 5 of reprogramming an equal number of mCHERRY+ and mCHERRY− 
cells (8 × 103 cells/cm2 for each condition) were FACS-sorted and re-plated on feeder layer in the presence of 
ESCs media + doxycycline (DOX). (J) Representative bright field images and fluorescence microscopy images, 
showing mCHERRY signal, of FACS-sorted mCHERRY+ and mCHERRY− cells after additional 8 days of DOX 
treatment. (K) Number of NANOG+ iPSC clones (represented as fold change and mean of n = 2 independent 
experiments) counted at day 18 of DOX treatment after re-plating. (L) Quantitative real-time PCR showing 
Peg3 expression levels (n = 2 independent experiments). (B,C,K,L) Data are represented as fold change (2−ΔΔCt) 
and means ± SE. Asterisks indicate statistical significance calculated by unpaired two-tailed t test analysis 
(*p < 0.05). Scale bar is 200 μm (F,G,J).
www.nature.com/scientificreports/
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Figure 4. Peg3 silencing causes mitochondrial impairment. (A) Quantitative real-time PCR analysis showing 
mitochondrial DNA quantification in ESCs normalized over Gapdh genomic DNA region (B). Quantitative 
real-time PCR analysis of mitochondrial gene expression levels in ESCs. (C,D) Representative western-blots 
(out of n = 2 independent experiments) showing PEG3 silencing efficiency and the level of mitochondrial 
proteins such as OPA1, DRP1 (C) and VDAC1 (D) in shCtrl and shPeg3 transduced ESCs. (E) Quantitative 
real-time PCR analysis showing mitochondrial DNA quantification in MEFs normalized over Gapdh genomic 
DNA region. (F) Quantitative real-time PCR analysis of mitochondrial gene expression levels in MEFs. (G) 
Representative western-blot (out of n = 2 independent experiments) showing PEG3 silencing efficiency 
and the level of mitochondrial proteins such as OPA1, DRP1 and VDAC1 in MEFs at day 0 after shCtrl and 
shPeg3 infection. (H,J) Representative fluorescence microscopy images and higher magnification of the 
selected area of MEFs at day 0 (H) and 5 (J) of reprogramming transduced with either shCtrl or shPeg3, 
showing mitochondria morphology stained with MitoTracker Green (MTG). Scale bar is 20 μm and nuclei 
are stained with Hoechst 33342. (I,K) Box plot representing mean mitochondrial branch length quantification 
(corresponding to the average length of all branches) in shCtrl and shPeg3 infected MEFs and day 0 (I) and 
day 5 (K) of reprogramming. (L,M) Box plot representing mean mitochondrial network size quantification 
www.nature.com/scientificreports/
8SCIentIfIC RePoRTS | 7: 9705  | DOI:10.1038/s41598-017-10016-7
Peg3 regulates mitochondria mass and function during somatic cell reprogramming. 
Pluripotent stem cells are normally characterized by low OXPHOS that increases with differentiation15–19. 
Moreover, a metabolic switch from OXPHOS toward glycolysis, which is associated with the reduction of mito-
chondrial activity and increased cell proliferation, is indispensable for the iPSC generation process14, 20, 35–39. 
Interestingly, Peg3 has been previously described to bind to genes that control mitochondrial functions, (Ndufs7, 
Ndufs8, Sdhb) and tissue development11, 12. In particular, Peg3 can recognize specific binding sites in the promoter 
regions through a specific consensus DNA-binding motif and its depletion can affect the expression of the cor-
responding genes11. During somatic cell reprogramming Ndufs8 and Sdhb expression has been associated with 
increased mitochondrial mass, cell size and low number of generated iPSCs37. Based on previously reported data, 
we asked whether Peg3 perturbation could alter mitochondrial gene expression and mitochondrial activity in 
both pluripotent stem cells and during somatic cell reprogramming.
By measuring both mitochondrial DNA amount and expression of mitochondrial-related genes, we observed 
a general downregulation in Peg3 depleted ESCs, as compared to the control (Fig. 4A and B). However, this was 
translated only into a minor decrease in the levels of proteins that control mitochondrial dynamics (such as OPA1 
and DRP140) and of proteins of the outer mitochondrial membrane, such as VDAC141 (Fig. 4C and D). In paral-
lel, we also analyzed mitochondrial potential by performing FACS-analysis of tetramethylrhodamine ethyl ester 
(TMRE) intensity16, 42. This showed only a minor, not significant, decrease after Peg3 silencing (Supplementary 
Figure 4A). Perhaps, this poor effect was due to the fact the Peg3 endogenous level was very low in ESCs and its 
further downregulation did not induce major changes in the mitochondrial activity. As control, we ensured that 
TMRE intensity was strongly and significantly downregulated after 16 h treatment of ESCs with the un-coupler 
carbonyl cyanide-m-chlorophenylhydrazone (CCCP)43, but not with ethanol (EtOH) (Supplementary Figure 4B), 
indicating good specificity and sensitivity of the TMRE assay. To further investigate the correlation between Peg3 
levels and mitochondrial activity in ESCs we analyzed mitochondrial gene expression during EB differentiation 
of Peg3 depleted ESCs. As expected, both shCtrl and shPeg3 infected ESCs could form normal EB structure 
(Supplementary Figure 4C). However, the expression levels of differentiation markers Fgf5 and Gata4 (markers 
of ecto- and mesoderm layer, respectively), were lower in the Peg3 depleted EBs when compared to the control 
(Supplementary Figure 4D). Interestingly, also mitochondria gene expression followed Peg3 expression during 
EB differentiation, suggesting a delay in differentiation in ESCs carrying Peg3 KD (Supplementary Figure 4E).
Since Peg3 KD only showed a mild phenotype in ESCs we asked whether its downregulation was effective in 
MEFs and NSCs that both express high endogenous Peg3 levels. First, we analyzed mitochondrial DNA amount 
and mitochondrial related gene expression in MEFs carrying either pLKO-shCtrl or pLKO-shPeg3 silencing con-
structs. These were significantly downregulated after Peg3 inhibition (Fig. 4E and F). Moreover, mitochondrial 
proteins (OPA1, DRP1, VDAC1) showed drastic reduced levels in shPeg3 infected MEFs as compared to control 
(Fig. 4G). Interestingly, MEFs carrying Peg3 KD displayed smaller cell size and less elongated mitochondria both 
at day 0 and at day 5 of reprogramming (Fig. 4H and J), suggesting that Peg3 inhibition could induce mitochon-
dria structural remodeling. To further characterize the effect of Peg3 inhibition on mitochondria morphology we 
quantified mitochondrial branch length by using Mitochondrial Network analysis (MiNA) toolset44 (Fig. 4I and K 
and Supplementary Figure 4F and G). Indeed, both mean and median branch length were significantly lower in 
Peg3 depleted MEFs at day 0 (Fig. 4I and Supplementary Figure 4F) and day 5 of reprogramming (Fig. 4K and 
Supplementary Figure 4G). Additionally, the mean mitochondrial network size, which indicates the number of 
branches per network44, was again lower in shPeg3 infected MEFs with respect to the control (Fig. 4L and M). 
These results indicate that Peg3 inhibition correlates with less elongated and less branched mitochondria in 
MEFs, both at day 0 and 5 of reprogramming. Furthermore, at day 0 of reprogramming both mitochondrial mass 
and potential, according to the FACS-analysis profile of MitoTracker Green (MTG) and TMRE respectively43, 45, 46, 
were lower upon Peg3 silencing with the respect to the control (Fig. 4N and Supplementary Figure 4H–L). In 
line with previously reported data37, the intensity of MTG and TMRE decreased during reprogramming from 
day 0 to day 5 in both conditions; however it was maintained even lower in Peg3 depleted MEFs (Fig. 4N and 
Supplementary Figure 4H–L). All in all, these data suggest that Peg3 inhibition induces mitochondria morphol-
ogy remodeling during somatic cell reprogramming.
Peg3 silencing induced reduction of TMRE intensity also in NSCs (Fig. 5A), although the mitochondrial mass 
did not decrease in this case, as shown by the MTG intensity (Fig. 5B). As in the case of MEFs, Peg3 silencing 
correlated with lower mitochondrial related gene expression and mitochondrial DNA levels (Fig. 5C,D and E). 
These observations indicate that Peg3 KD causes an overall mitochondrial impairment in both MEFs and NSCs.
To further explore the correlation between Peg3 levels and mitochondrial activity we transfected ESCs with 
either EF1α-EV-SV40-mCherry or EF1α-Peg3-SV40-mCherry and we measured MTG intensity within the 
mCHERRY positive population in each condition. PEG3 overexpressing ESCs (Supplementary Figure 5A) dis-
played higher MTG intensity when compared to the control (EV) (Supplementary Figure 5B) and higher levels of 
outer mitochondrial membrane protein, VDAC1 (Supplementary Figure 5C). Interestingly, PEG3 overexpression 
also correlates with increased protein levels of the mitochondrial oxidative complexes. In particular, ATP synthase 
(corresponding to the number of branches per network) in shCtrl and shPeg3 infected MEFs and day 0 (L) and 
day 5 (M). (N) Quantification of MTG intensity from day 0 to day 5 of reprogramming in MEFs transduced 
either with shCtrl or shPeg3. (A,B,E,F,N) Data are represented as fold change (2−ΔΔCt) and means ± SE of n = 3 
independent experiments. Asterisks indicate statistical significance calculated by unpaired two-tailed t test 
analysis (*p < 0.05; **p < 0.01; ***p < 0.001). For western-blot analysis β-Tubulin and Vinculin were used as 
loading controls and densitometric analysis was carried out by using ImageJ software. The quantification reflects 
the relative amounts as a ratio of each protein band relative to their loading control.
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subunits, corresponding to complex 5 (CV- ATP5A) and ubiquinol-cytochrome c reductase subunits correspond-
ing to complex 3 (CIII-UQCRC2) were upregulated upon PEG3 overexpression (Supplementary Figure 5D). In 
line with these results, Peg3 overexpression increased the protein levels of the succinate dehydrogenase complex 
subunit A (SDHA), the iron-sulfur subunit (SDHB) (Supplementary Figure 5E) and mitochondrial DNA amount 
(Supplementary Figure 5F) in ESCs.
Finally, to strengthen our hypothesis of Peg3 controlling mitochondrial activity we also transfected HEK293T 
cells with either EF1α-EV-SV40-mCherry or EF1α-Peg3-SV40-mCherry constructs and analyzed MTG intensity 
level within the mCHERRY positive cell population. Also in this case, the mCHERRY+ cells overexpressing PEG3 
(Supplementary Figure 5G) displayed higher mitochondrial mass with the respect to the mCHERRY+ overex-
pressing an empty vector (EV), as shown by MTG intensity levels (Supplementary Figure 5H).
Figure 5. Peg3 levels correlate with mitochondrial mass and activity. (A,B) Representative FACS plot analysis 
and quantification of tetradmethylrhodamine ethyl ester (TMRE) (A) and MTG (B) intensity in NSCs 
transduced with either shCtrl or shPeg3 and selected with hygromycin (n = 3 independent experiments). (C) 
Quantitative real-time PCR analysis of mitochondrial gene expression levels in NSCs represented as fold change 
(2−ΔΔCt) and means ± SE of n = 3 independent experiments. (D) Quantitative real-time PCR analysis showing 
mitochondrial DNA quantification in NSCs calculated over Gapdh genomic DNA region (n = 3 independent 
experiments). (E) Representative western-blot (n = 1) showing PEG3 silencing efficiency and the levels of 
mitochondrial proteins such as OPA1, DRP1, and VDAC1 in shCtrl or shPeg3 transduced NSCs. (F) Schematic 
representation explaining the role of Peg3 in pluripotent stem cells and during somatic cell reprogramming. 
Asterisks indicate statistical significance calculated by unpaired two-tailed t test analysis (*p < 0.05; **p < 0.01). 
For western-blot analysis β-Tubulin was used as loading control and densitometric analysis was carried out by 
using ImageJ software. The quantification reflects the relative amounts as a ratio of each protein band relative to 
their loading control.
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All in all, these data suggest that Peg3 could regulate mitochondrial structure, mass and activity within dif-
ferent cell types. Moreover, perturbation of Peg3 expression levels affect the efficiency of somatic cell repro-
gramming process, which correlates with the mitochondria undergoing structural and functional modifications, 
leading to metabolic changes.
Discussion
Peg3/Pw1 is widely expressed during embryonic and fetal development and in particular in the muscle, neuronal 
lineages and placenta1, 2, 47. Moreover, high Peg3 levels have been observed in many adult tissues such as brain, 
ovary, testis and in adult stem cells3, 48. In this study we observed that Peg3 is expressed at very low levels in ESCs, 
while it is upregulated during ESC differentiation towards NSCs or in embryoid bodies. These results are consist-
ent with the published observation that Peg3 starts to be robustly expressed in the mouse embryo at the beginning 
of the gastrulation during muscle development and neurogenesis1, 2.
Although ESCs showed low endogenous Peg3 expression when grown in serum-Lif medium, a further tran-
scriptional downregulation was observed in 2i-Lif cell culturing condition. ESCs cultured in 2i-Lif medium have 
been shown to be more similar to the inner cell mass24, while ESCs cultured in serum-Lif medium display heter-
ogeneous pluripotency marker expression and are subject to spontaneous differentiation events49. This difference 
might explain the distinct levels of Peg3 in these two ESC pluripotent states. Interestingly, Peg3 knockdown in 
ESCs cultured in serum-Lif led to an increase of pluripotency marker expression and AP+ signal, although Peg3- 
silenced cells did not reach the ground state pluripotency that ESCs reach when grown in the 2i-Lif medium. 
Indeed, REX1-dGFP ESCs are almost all GFP positive when cultured in 2i-Lif medium23. This was not observed 
in the case of Peg3 depleted ESCs. However, Peg3 depleted ESCs showed a delay in differentiation toward NSCs, 
suggesting that Peg3 KD might prevent differentiation and enhance pluripotency, even though it was not suffi-
cient to allow the cells to reach the ground state pluripotency. Additionally, Peg3 silencing caused a delay in the 
ecto- and mesodermal marker expression during EB differentiation. On the contrary these differentiation mark-
ers were upregulated in PEG3 overexpressing ESCs. These results suggest that Peg3 plays an important role in cell 
fate determination, which further confirm previous reported data showing Peg3 expression in muscle and neural 
lineage formation during embryo development1, 2.
In addition to their differentiation capability, pluripotent stem cells are characterized by a high proliferative 
capacity that normally correlates with elevated glycolytic metabolism and reduction of oxidative phosphorylation 
(OXPHOS) within the mitochondrial complexes18, 19, 36, 50–53. The glycolytic flux decreases dramatically when ESCs 
start to differentiate15, 54–56 and, in parallel, mitochondrial OXPHOS increases. For instance, the switch from glyc-
olysis to mitochondrial oxidative metabolism is characterized also by mitochondria maturation and it is necessary 
to allow cardiac specification16, 54. These published observations are again consistent with our data, which show a 
strong and significant increase of Peg3 expression during EB formation. Therefore Peg3 expression correlates with 
high oxidative metabolism that is necessary to boost cell fate transition. In line with these results, Peg3 has been 
reported to mediate muscle stem cell homeostasis57. Interestingly, several cancer cell lines, including glioma, have 
been shown to downregulate Peg36. Similar to ESCs, glioma stem cells and many cancer cells are characterized 
by high glycolytic metabolism58, confirming our observation that Peg3 expression can be associated to OXPHOS 
metabolism rather than glycolysis.
A switch from OXPHOS to glycolysis has been shown to occur during reprogramming of somatic cells into 
iPSCs20, 35, preceding the reactivation of pluripotency markers59 and it is associated with rapidly proliferating cells. 
Moreover promotion of glycolysis or stimulation of OXPHOS can enhance or impair somatic cell reprogramming 
process, respectively20, 35. In a similar way, in our study we observed that Peg3 silencing could enhance the yield of 
iPSC generation starting from either NSCs or MEFs, suggesting that its effect controls the dynamics of the repro-
gramming process and, importantly, it is not cell type specific. This is supported by the finding that even a mod-
est Peg3 overexpression impairs the generation of NANOG+ iPSC clones. In particular, we observed that Peg3 
silencing caused a generalised mitochondrial impairment, as shown by the decrease of MTG and TMRE intensity 
and mitochondrial gene expression downregulation, such as Ndufs8, Sdhb, Drp1 and Opa1. This phenotype was 
particularly evident in MEFs at day 0 and during the reprogramming process. Consistently, Peg3 has been shown 
to bind directly to Ndufs7, Ndufs8, Sdhb and other mitochondrial genes in a sequence specific manner, behaving, 
therefore, as a DNA-binding protein11, 12. These nuclear encoded mitochondrial genes are involved in the main-
tenance of energy homeostasis, further supporting the connection between Peg3 and mitochondrial activity. 
Interestingly, we observed that Ndufs8, Sdhb and Peg3 expression levels correlated in ESCs, NSCs and MEFs sug-
gesting that Peg3 can control common genes in these different cell types. Ndufs8 and Sdhb encode for subunits of 
the NADH-ubiquinone oxidoreductase complex and the succinate dehydrogenase complex, respectively. These 
proteins are located within the mitochondria membrane and they regulate OXPHOS60, 61.
Additionally, we observed that Peg3 silencing caused a decrease in mitochondrial mass, as compared to 
the control, suggesting a possible reduction also in OXPHOS. Accordingly, Peg3 depleted MEFs displayed 
less branched and elongated mitochondria during somatic cell reprogramming. Indeed, the remodeling of the 
mitochondria structure62 and the reduction of mitochondrial mass37 was previously associated with the repro-
gramming process. Moreover, we observed the opposite phenotype following Peg3 overexpression, which also 
correlates with upregulation of the OXPHOS protein complexes, thus further confirming its effect on mitochon-
dria. This role of Peg3 in the regulation of metabolic changes could be extended to other cell types and tissues. 
Previous published data report that Peg3 can regulate mammalian growth and behavior63. In particular, Peg3 
expression has been detected in the embryo and adult brain and mutations in the Peg3 gene cause behavioral 
defects, such as impairment of maternal behavior that could be caused by defective neuronal connectivity63. 
Mature neurons rely on oxidative phosphorylation to meet high-energy demands; consequently defects in mito-
chondria structure and metabolism are often associated with neurodegenerative disorders64–66. Moreover other in 
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vivo models further support the involvement of Peg3 in metabolic regulation and our observations: for example, 
mice carrying a targeted mutation in Peg3 gene displayed increased body fat67. Finally, downregulation of Peg3 
and other paternally expressed genes in adipocytes has been shown to be involved in the paternal transmission of 
high-fat-diet induced obesity68.
Overall our study demonstrates that Peg3 expression levels anti-correlate with pluripotency and increase grad-
ually upon ESC differentiation. Moreover, downregulation of Peg3 enhances the efficiency of reprogramming of 
differentiated cells towards pluripotency. In particular, Peg3 can alter mitochondrial activity, which could con-
tribute to the OXPHOS-to-glycolysis metabolic switch (Fig. 5F). Therefore Peg3 can be regarded as a new and 
important player of metabolic and molecular changes that in turn can control cell fate transition.
Material and Methods
iPSC induction and ESC differentiation. The reprogramming experiments of OKSM 4F-MEFs were 
routinely conducted in gelatin-coated plates, in ESC culture medium supplemented with 2 μg/ml doxycycline, 
as previously described28. For WT MEFs reprogramming was induced through OKSM or OKS infection. NSCs 
were reprogrammed through OKM overexpression. In particular, 2 × 105 MEFs and NSCs were transduced with 
OKSM/OKS/OKM concentrated retroviral particles. After 48 h the infected cells were plated on feeder layer and 
the media was switched to ESC media for 16 additional days. Doxycycline was added up to day 12 of reprogram-
ming. The number of reprogrammed iPSC clones was counted at day 16 of reprogramming.
Mitochondria mass and potential quantification. Mitochondria were stained in living cells with 
MitoTraker Green (Invitrogen M7514) (150 nM) for 15 min at 37 °C and 5% CO2. MitoTraker Green incorpo-
ration was quantified by BD LSR Fortessa flow cytometer and analyzed by Flowjo software. Unstained cells were 
used as negative control and DAPI (SIGMA 09542) staining was performed to exclude dead cells from the anal-
ysis. Before FACS analysis the samples were filtered with 35μm mesh size filters (Corning Life Sciences 352235) 
to avoid aggregates.
Mitochondria potential was assessed by Mitostatus TMRE staining (BD Pharmingen 564696). Living cells 
were labeled with Mitostatus TMRE (100 nM) for 15 min at 37 °C and 5% CO2. Mitochondrial potential was quan-
tified by BD LSR Fortessa flow cytometer and analysed by Flowjo software. Unstained cells were used as negative 
control and DAPI (SIGMA 09542) staining was performed to exclude dead cells from the analysis. Before FACS 
analysis the samples were filtered with 35μm mesh size filters to avoid aggregates.
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